Taking aim at ALK across the blood-brain barrier

Journal of Thoracic Oncology

Volumn 8, Issue 4, 2013, Pages 389-390

  Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

BLOOD BRAIN BARRIER; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID LEVEL; DRUG TARGETING; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84875399271     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182864e7c     Document Type: Editorial

References (17)

1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Pdated resultsfrom a phase 1 study. Lancet Oncol 2012;13:1011-1019
2. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2012;30(15-suppl): 7533
3. Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 2013;24:59-66
4. Kris MG, Johnson BE, Kwiatkowski DJ, et al: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma the NCI's Lung Cancer Mutation Consortium (LCMC). 2011 ASCO Annual Meeting. Abstract CRA7506
5. Bunn PA Jr, Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, Franklin W. Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol 2010;5:1113-1115
6. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2013;8:e3-e5
7. Maillet D, Martel-Lafay I, Arpin D, et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013;8:e30-e31
8. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12:1004-1012
9. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-Addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-1814
10. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-e445
11. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-28
12. Kaneda H, Okamoto I, Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small cell lung cancer. J Thorac Oncol 2013;8:e32-e33
13. Chi AS, Batchelor TT, Kwak EL, et al. Rapid radiographic and clinical improvement after treatment of a MET-Amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012;30:e30-e33
14. Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010;68:264-268
15. Mehra R, Camidge DR, Sharma S, et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. ASCO Proc 2012; 3007
16. Gettinger S, Weiss GJ, Salgia R, et al. A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. ESMO 37th Annual Meeting 2012; Abstract 4390
17. Lin NU, Lee EQ, Aoyama H, et al. Response assessment in neuro-oncology (A Report of the RANO Group): Challenges relating to solid tumor brain metastases in clinical trials, part 1: Patient population, response, and progression (Submitted